CN203280801U - Artificial urine outflow channel - Google Patents
Artificial urine outflow channel Download PDFInfo
- Publication number
- CN203280801U CN203280801U CN2013202894300U CN201320289430U CN203280801U CN 203280801 U CN203280801 U CN 203280801U CN 2013202894300 U CN2013202894300 U CN 2013202894300U CN 201320289430 U CN201320289430 U CN 201320289430U CN 203280801 U CN203280801 U CN 203280801U
- Authority
- CN
- China
- Prior art keywords
- cavity
- cell
- artificial urine
- cultivated
- urine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
The utility model belongs to a field of medical devices, and relates to an artificial urine outflow channel comprising a pen-container-shaped cavity with one opened end and one closed end, wherein the cavity is prepared by polylactic acid - glycolic acid copolymer, has a thickness of 2-5 mm, and comprises holes having a diameter 50-200 [mu]m, a volume of the holes is 65-98 % of that of the cavity, the holes facing an inner surface in the cavity are cultivated with urothelial cells, the holes facing an outer surface in the cavity are cultivated with smooth muscle cells, and a tube body near the closed end in the cavity has two interfaces fitted with bilateral ureters. The polylactic acid - glycolic acid copolymer has degradable characteristics, and thus should be cultivated into the organism in a short time after preparation so as to continue a biological activity. According to the artificial urine outflow channel provided by the utility model, cutting of normal gastrointestinal tract as bladder substitute can be prevented; autologous cell transplantation can prevent immune rejection, and the autologous cells can rapidly build blood supply after being cultivated into body so as to maintain basic biological activity and function.
Description
Technical field
This utility model relates to a kind of artificial urine efferent tract, belongs to technical field of medical instruments.
Background technology
A lot of diseases (as: wound, tumor, operation and congenital factors etc.) all can cause the bladder disappearance, clinically the most commonly bladder excision that causes of tumor of bladder.After the bladder excision, urine can't be discharged by normal approach, needs the efferent tract that builds an interim storage of urine and urine is excreted.Conventional way is that the gastrointestinal tract that cuts one section health of patient is engaged in this profession as urine flow at present, with patient's bilateral ureteral, coincide and carries out the urinary diversion operation, and the gastrointestinal tract of cut-out coincide and couples together again.This modus operandi need to intercept one section digester tube, not only increase patient's misery, prolongation operating time, increase operation risk, and cause a lot of complication, even cancerate as anastomotic stoma leakage of urine, graft necrosis, entocele formation, intestinal obstruction, secreting mucus, urinary tract infection, electrolyte disturbance, formation calculus etc.
Along with the development of society, economy and modern science, people are also more and more higher for the requirement of medical services.This way of with the cost of sacrificing an organ, rebuilding another organ has not met the demand for development of modern science, urgently needs a kind of artificial material to substitute.Human skin, osseous tissue have all had biotech firm to develop substitute products at present, but having no the product development of artificial urine efferent tract is applied to clinical.
What time following desirable tissue engineering bladder require to meet: 1. can increase with the urine storage capacity; 2. outer surface is distributing according to certain tactic smooth muscle layer; 3. can get excited by inducing neural after reaching a constant volume, control smooth muscle and shrink to a direction, form micturition; 4. form good blood supply and keep the biological activity of bladder.Be subject to the development that present organizational project learns a skill, the bladder that builds at present this perfect condition hardly may.But tissue engineering research has at present spread all over various cells and material, and a urine flow waterproof of structure, interim storage of urine is engaged in this profession and can be realized.
The present inventor is engaged in the organizational project correlational study for a long time.The complex repairing ureter that form by research rabbit bladder acellular matrix and Urothelial cell early stage, this complex have reached the effect of waterproof, drainage of urine, succeed.Could obtain because acellular matrix still needs donor organ, be difficult to batch production.
This utility model design has adopted synthetic material Poly(D,L-lactide-co-glycolide (PLGA) as the material that supports cell, and it has degradable, has certain toughness to build three-dimensional configuration, degradation time and the advantages such as porosity capable of regulating, no cytotoxicity.
This novel synthetic urine's efferent tract need not to destroy the patient health organ again, increase external by extracting self cell, implant again and Ureteral anastomosis after being built into complex with support material, the urine in ureter by the urine flow of synthetic engage in this profession flow out external.
The utility model content
Technical problem to be solved in the utility model is to provide a kind of artificial urine efferent tract.
Artificial urine efferent tract of the present utility model, comprise an end opening, the pen container shape cavity of other end sealing, cavity is made by Poly(D,L-lactide-co-glycolide (PLGA), thickness is 2～5mm, includes the hole of diameter 50～200um in cavity, and the hole volume is 65%～98% of cavity; Cavity is planted and is implanted with Urothelial cell in the hole of inner surface, cavity interior kind of hole on surface outward is implanted with smooth muscle cell;
Described cavity is near also having two interfaces that coincide with bilateral ureteral on the cavity of sealing one end.
The length of described cavity is preferably 10～25cm, and diameter is preferably 2～5cm.
Described interface diameter is 0.5～2.0cm.
The Urothelial cell that described Urothelial cell can form for the differentiation of patient self Urothelial cell or other cell induction.
The cavity of described artificial urine efferent tract has certain mechanical strength, can support Growth of Cells, seek connections with.Inner surface is paved with Urothelial cell, by external aseptic condition, adds conventional epithelium culture medium culturing, makes Urothelial cell and cavity form interlaced integral body.Closely connect between Urothelial cell, the UPK albumen of emiocytosis forms watertight composition, can isolate urine, prevents that the noxious substance in urine from infiltrating, and can play the effect that prevents the urine infiltration.Outer surface is paved with smooth muscle cell, maintains the tension force that this urine flow is engaged in this profession.This urine flow cecum of engaging in this profession is reserved the interface of using with Ureteral anastomosis, and opening is fixed by skin and subcutaneous tissue, and opening leads to external, is connected the collection urine with ostomy bag.
PLGA material progressively degraded in vivo in artificial urine efferent tract of the present utility model,, by the substrate replacement degradation material of emiocytosis, form the form of new support holdout device.
The preparation method of artificial urine efferent tract of the present utility model, comprise the steps:
1) after the PLGA material dissolves, sneak into the sodium chloride particle of 50～200um diameter, stir, pour in mould, after the PLGA material cured, forming thickness is the flat board of 2～5mm; Immerse in pure water, sodium chloride particle is dissolved, form hole, hole accounts for the ratio of the dull and stereotyped cumulative volume of PLGA between 65%～98%;
2) after body or reduced immunogenicity allosome or heterogenous cell extract by the mode of biopsy, induce differentiation external, add the Urothelial cell somatomedin, make it to form and have the Urothelial cell characteristic, amplification is at least 2 * 10 subsequently
6/ cm
2Density;
3) after body or reduced immunogenicity allosome or heterogenous cell extract by the mode of biopsy, induce differentiation external, add the smooth muscle cell growth factor, make it to form and have the smooth muscle cell characteristic, amplification is at least 2 * 10 subsequently
6/ cm
2Density;
4) the dull and stereotyped horizontal positioned of PLGA, one side up is the A face, and one side down is the B face, first smooth muscle cell is planted in the dull and stereotyped A face of PLGA, cultivated 1 day in culture fluid under aseptic condition, make smooth muscle cell enter and with PLGA, adhere to and form integral body from the A face by a large amount of holes;
5) again with the PLGA Flat plate turnover, B faces up, and ready cell with Urothelial cell feature before plantation was cultivated 1 day in culture fluid;
6) will plant the PLGA dull and stereotyped two long limit docking of cell, form pipe crimping, the B face of having planted Urothelial cell is positioned at the tube chamber inboard, the A face of having planted smooth muscle cell is positioned at the tube chamber outside, joint is sewed up with absorbable thread, pipe crimping one end is sewn closed also, and reserves two openings on the body of this end, makes artificial urinary tract efferent tract.
Use artificial urine efferent tract of the present utility model, can avoid excising normal gastrointestinal tract and carry out bladder and substitute, reduced operation time, reduced operating difficulty and risk, avoided a series of post-operative complication.Autogenous cell transplantation has been avoided immunological rejection, and after implanting, the blood supply of energy Rapid Establishment, keep its basic biologic activity and function.
Description of drawings
The tabular PLGA material of Fig. 1 porous (triangle shows one jiao of enlarged drawing cutting, and stain represents hole).
Fig. 2 has planted the PLGA material of cell.
The PLGA material that Fig. 3 has planted cell is curling.
The artificial urine efferent tract that the dull and stereotyped cutting of Fig. 4 PLGA, stitching obtain.
The application (with artificial example) in vivo of this device of Fig. 5.
The 1-kidney, 2-ureter, 3-interface, 4-ostomy bag, 5-urine.
The specific embodiment
Now the utility model is described in further detail by reference to the accompanying drawings.
Artificial urine efferent tract of the present utility model, comprise an end opening, the pen container shape cavity of other end sealing, cavity is made by Poly(D,L-lactide-co-glycolide (PLGA), thickness is 2～5mm, includes the hole of diameter 50～200um in cavity, and the hole volume is 65%～98% of cavity; Cavity is planted and is implanted with Urothelial cell in the hole of inner surface, cavity interior kind of hole on surface outward is implanted with smooth muscle cell;
Described cavity is near also having two interfaces that coincide with bilateral ureteral on the cavity of sealing one end.
Above-mentioned artificial urine efferent tract can be made in accordance with the following methods:
1) after the PLGA material dissolves, the sodium chloride particle of sneaking into 50～200um diameter stirs, pour length 10～25cm into, width 6.3～15.7cm, in the mould of thickness 2～5mm, after the PLGA material cured, immerse in pure water, sodium chloride particle is dissolved, form hole, hole size is the sodium chloride particle size, and hole accounts for the ratio of PLGA material cumulative volume between 65%～98%;
2) after body or reduced immunogenicity allosome/heterogenous cell extract by the mode of biopsy, induce differentiation external, add the Urothelial cell somatomedin, make it to form and have the Urothelial cell characteristic, amplification is at least 2 * 10 subsequently
6/ cm
2Density, carry out cell and identify that confirmation cell purity, cell viability, cell surface antigen etc. meet the Urothelial cell feature;
3) mode of describing similar 2) is extracted and the amplification in vitro smooth muscle cell;
4) the PLGA material horizontal is placed arbitrarily, and one side up is defined as the A face, and one side down is defined as B face (Fig. 1), and A in subsequent descriptions, the definition of B face no longer change (after being 180 ° of flip horizontals, the A face becomes one side down) with the upset of material;
5) first smooth muscle cell is planted in PLGA materials A face, cultivated 1 day in culture fluid under aseptic condition, make smooth muscle cell enter and with material, adhere to and form integral body from PLGA materials A face by a large amount of holes;
6) will plant the PLGA material upset of smooth muscle cell, up, ready cell with Urothelial cell feature before plantation, do not cultivate 1 day (Fig. 2) with culture fluid to the one side of repopulating cell (B face) again;
7) will plant the PLGA material two long limits docking of cell, absorbable thread is sewed up (end is reserved two openings), forms pipe crimping, and pipe crimping one end is sewn closed also, makes operational urine flow engage in this profession (Fig. 3,4)
The application mode of this device:
1) this device is applicable to organism (comprising the people) the bladder disappearance that any reason causes;
2) as required, the pipeline of the customization different size of individuation, gather individual cells and make;
3) in the whole implantable bioartificial bodies of this device, cecum is reserved opening and is connected with two ureters, opening and organism surface skin coincide, urine enters in this device by ureter, and external in the opening outflow of body surface via device, outer body can connect the ostomy bag of present wide clinical application and collect urine (Fig. 5).
Claims (4)
1. an artificial urine efferent tract, is characterized in that, comprises an end opening, the pen container shape cavity of other end sealing, cavity is made by Poly(D,L-lactide-co-glycolide, and thickness is 2～5mm, the hole that includes diameter 50～200um in cavity, hole volume are 65%～98% of cavity;
Cavity is planted and is implanted with Urothelial cell in the hole of inner surface, cavity interior kind of hole on surface outward is implanted with smooth muscle cell;
Described cavity is near also having two interfaces that coincide with bilateral ureteral on the body of sealing one end.
2. artificial urine efferent tract according to claim 1, is characterized in that, the length of described cavity is 10～25cm, and diameter is 2～5cm.
3. artificial urine efferent tract according to claim 1, is characterized in that, described interface diameter is 0.5～2.0cm.
4. artificial urine efferent tract according to claim 1, is characterized in that, described Urothelial cell is the Urothelial cell that patient self Urothelial cell or the differentiation of other cell induction form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013202894300U CN203280801U (en) | 2013-05-24 | 2013-05-24 | Artificial urine outflow channel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013202894300U CN203280801U (en) | 2013-05-24 | 2013-05-24 | Artificial urine outflow channel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203280801U true CN203280801U (en) | 2013-11-13 |
Family
ID=49537184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013202894300U Expired - Fee Related CN203280801U (en) | 2013-05-24 | 2013-05-24 | Artificial urine outflow channel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203280801U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251979A (en) * | 2013-05-24 | 2013-08-21 | 武汉大学 | Manual urine outflow tract and preparation method thereof |
-
2013
- 2013-05-24 CN CN2013202894300U patent/CN203280801U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251979A (en) * | 2013-05-24 | 2013-08-21 | 武汉大学 | Manual urine outflow tract and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6689608B1 (en) | Porous biodegradable polymeric materials for cell transplantation | |
| EP2931179B1 (en) | Process for growing a heart valve in three-dimensions | |
| CN101282652B (en) | Prevascularized devices and related methods | |
| CN103200973B (en) | Devices and methods for treating fistulae and other bodily openings and passageways | |
| US7462471B2 (en) | Porous biodegradable polymeric materials for cell transplantation | |
| KR20170051493A (en) | Medical/surgical implant | |
| US11058534B2 (en) | Tubular prostheses | |
| US20050209687A1 (en) | Artificial vessel scaffold and artifical organs therefrom | |
| WO1994025079A1 (en) | Porous biodegradable polymeric materials for cell transplantation | |
| WO2011137394A1 (en) | Breast reconstruction device and methods | |
| JP2013521882A (en) | Cell scaffolding construct | |
| US20070198053A1 (en) | Cuff member | |
| EP4125715A1 (en) | In vivo tissue engineering devices, methods and regenerative and cellular medicine employing scaffolds made of absorbable material | |
| Leonhäuser et al. | Two differentially structured collagen scaffolds for potential urinary bladder augmentation: proof of concept study in a Göttingen minipig model | |
| CN110878285A (en) | Chip organ model for screening bladder tumor chemotherapy drugs and manufacturing method thereof | |
| CN203280801U (en) | Artificial urine outflow channel | |
| US11633583B2 (en) | Implantable interface device | |
| CN103251979A (en) | Manual urine outflow tract and preparation method thereof | |
| Adamowicz et al. | Constructing artificial urinary conduits: current capabilities and future potential | |
| CN204219093U (en) | A kind of degradable spherical faux bladder | |
| Leonhauser et al. | Two differentially structured collagen scaffolds for potential urinary bladder augmentation: proof of concept study in a Gottingen minipig model | |
| JP2006238987A (en) | Substrate for forming connective tissue sheet (biosheet) and method for producing biosheet | |
| WO2003082366A1 (en) | Tissue engineering scaffold material, aritficial vessel, cuff member and coating for implants | |
| CN105477680A (en) | Preparation method of in-vivo artificial blood vessel | |
| CN104188734B (en) | The spherical artificial urinary bladder of a kind of degradable |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131113 Termination date: 20210524 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |